Clinical trial
Tapentadol (CG5503)
NCT00421928 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00421928 |
|---|---|
| Title | Tapentadol (CG5503) |
| Official title | A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Grünenthal GmbH Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoarthritis, Knee, Pain |
| Intervention type | Drug |
| Interventions | oxycodone, placebo, tapentadol (CG5503) |
| Enrollment | 1,030 |
| Start date | Jan 1, 2007 |
| Primary completion | Jul 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jan 15, 2007 |
| Last update posted | Apr 18, 2012 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: